INSM - Why Is Inflammatory Diseased-Focused Insmed Stock Soaring On Tuesday? | Benzinga
Insmed Incorporated (NASDAQ:INSM) shares are trading higher after the company released topline results from the ASPEN Phase 3 study of brensocatib in patients with non-cystic fibrosis bronchiectasis.
Non–cystic fibrosis bronchiectasis is a chronic inflammatory condition of the lungs associated with respiratory infections, daily coughing, and sputum.
The study met its primary endpoint, with both dosage strengths of brensocatib demonstrating statistically significant reductions in the annualized rate of pulmonary exacerbations (PEs) versus placebo.
Brensocatib reduced pulmonary exacerbations by 21.1% at 10 mg dose versus placebo and ...